NeuBase Therapeutics, Inc. Skyrocketed
NeuBase Therapeutics, Inc. (NBSE:NASDAQ) soared at $0.99, representing a gain of 53.4%. On Thu, Nov 30, 2023, NBSE:NASDAQ touched a New 2-Week High of $0.99. From Thu, Nov 16, 2023, the stock recorded 55.56% Up Days and 40.00% Green Days
The stock spiked on Thu, Nov 30, 2023 at $1.51 with a volume of 14M+.
About NeuBase Therapeutics, Inc. (NBSE:NASDAQ)
Ohr Pharmaceutical Inc is a US-based pharmaceutical company which focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The lead product of the company is topical Squalamine is a novel therapeutic product which provides non-invasive therapy to improve visual outcomes. Its product pipeline includes SQUALAMINE LACTATE OPHTHALMIC SOLUTION 0.2%, SKS sustained release ocular drug delivery platform technology, Animal Model for Dry-AMD, and Non-Ophthalmology Assets.
Top 10 Gainers:
- Ampio Pharmaceuticals, Inc. (AMPE:NYSEMKT), 193.89%
- Signature Bank (SBNY:NASDAQ), 150%
- Soligenix, Inc. (SNGX:NASDAQ), 135.97%
- Incannex Healthcare Limited (IXHL:NASDAQ), 84.95%
- ImmunoGen, Inc. (IMGN:NASDAQ), 82.75%
- SeaChange International, Inc. (SEAC:NASDAQ), 74.22%
- Intelligent Bio Solutions Inc Com (INBS:NASDAQ), 61.35%
- Smart for Life Inc. (SMFL:NASDAQ), 58.55%
- NeuBase Therapeutics, Inc. (NBSE:NASDAQ), 53.38%
- Etao International Co. Ltd. (ETAO:NASDAQ), 50.6%